The dosing interval can be safely extended to every 3 weeks in patients with rheumatoid arthritis on a regimen of adalimumab and with serum trough concentrations of greater than 8 μg/mL, according to ...

In this section, we summarize the evidence on clinical effectiveness on the basis of the continuation of adalimumab therapy beyond RCTs, or in registry studies. OLT 3 (DE029) Healthy male and female ...

Fatigue is a high-priority symptom in patients with rheumatoid arthritis (RA), owing to its markedly detrimental effects on quality of life. Nonetheless, fatigue is rarely assessed by rheumatologists ...

NORTH CHICAGO, Ill., Oct. 20, 2025 /PRNewswire/ -- AbbVie (ABBV) today announced positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study evaluating the efficacy and safety of ...

ABBOTT PARK, Ill., Nov. 12, 2012 /PRNewswire/ -- Abbott today announced results from a post-hoc analysis of HUMIRA ® (adalimumab) data in early and long-standing moderate-to-severe rheumatoid ...

Please provide your email address to receive an email when new articles are posted on . Olokizumab demonstrated superiority compared with placebo and non-inferiority compared with adalimumab in ...

(HealthDay News) — The biosimilar ABP 501 has similar clinical efficacy and safety to adalimumab for the treatment of moderate-to-severe plaque psoriasis, according to a study published online in the ...

It is an exciting time to be a medical dermatologist, with the ongoing development of numerous safe and effective systemic treatments for several complex medical dermatologic diseases. For example, ...

Int J Clin Rheumatol. 2013;8(2):165-184. The most common AEs were injection site reactions, abdominal pain, headache and hypertension. Total AE rates, as well as serious AE rates, were mostly similar ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window It is an ...